NeuroScientific Biopharmaceuticals : Company Presentation

N O V E L D R U G T H E R A P I E S F O R N E U R O D E G E N E R A T I V E C O N D I T I O N S

nal use only

COMPANY PRESENTATION March 2022

A S X : N S B

nal use only

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd ("NeuroScientific", or "the Company"). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

nal use only

COMPANY HIGHLIGHTS

DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTIC

DRUGS

Developing peptide-based drugs with disease modifying potential for neurodegenerative conditions

EMTINB™: LEAD DRUG CANDIDATE WITH

DISEASE MODIFYING POTENTIAL

A first-in-class treatment for Alzheimer's disease, Multiple sclerosis and glaucoma

TRANSITIONING FROM PRECLINICAL TO CLINICAL

DEVELOPMENT IN 1H CY2022

EmtinB™is set to enter a first-in-human Phase I clinical trial in the first half of 2022

3

COMPANY OVERVIEW

		CAPITAL STRUCTURE			SHARE PRICE CHART
		ASX CODE	NSB
		SHARE PRICE (23/04/22)	$0.29
		SHARES ON ISSUE	143.5M
only		16.8M
		UNLISTED OPTIONS
		MARKET CAPITALISATION	$42M
		NET CASH POSITION	$9.5M
		TOP 20 SHAREHOLDERS	48%
use
		BOARD & MANAGEMENT
			PAUL RENNIE	MATT LIDDELOW		DR ANTON UVAROV	STEPHEN QUANTRILL
			CHAIRMAN	CEO & MANAGING DIRECTOR		EXECUTIVE DIRECTOR	NON-EXECUTIVE DIRECTOR
		Founder of Paradigm (ASX:PAR)	Experienced pharma executive		Founding Director of Actinogen (ASX:ACW)	20+ years corporate advisory
		Former COO of Mesoblast (ASX:MSB)	14+ years industry experience		Former equities analyst with Citigroup, US	Executive Chairman of McRae Investments
nal

4

ADDRESSING GLOBAL UNMET MEDICAL NEED IN

NEURODEGENERATIVE CONDITIONS

The underlying cause of most neurodegenerative conditions is not known

onlyMOST SEVERE TYPE OF		AGE OF ONSET 20-50Y		2nd LEADING CAUSE OF
	ALZHEIMER'S DISEASE		MULTIPLE SCLEROSIS		OPTIC NEUROPATHIES
		40M WORLDWIDEPATIENTS		$27B VALUEMARKET		70M GLAUCOMAINCIDENCE OF
use	DEMENTIA				BLINDNESS
	NO DISEASE MODIFING		NO EFFECTIVE DRUGS TO		CURRENT TREATMENT
		DRUGS AVAILABLE		TREAT LATER-STAGE OF		OPTIONS NOT SUITABLE FOR
				DISEASE		ALL PATIENTS
		DEVELOPING A SOLUTION IS CHALLENGING WHEN THE CAUSE IS NOT FULLY UNDERSTOOD
nal	NSB'S RESEARCH IS A POTENTIAL SOLUTION BY HARNESSING THE BODY'S DEFENSE
MECHANISMS TO COMBAT NEURODEGENERATIVE DISEASES
			5